Vitrotest SARS-CoV-2 IgA TK033
SARS-CoV-2 IgA antibody test
The new coronavirus caused a pandemic, which means it is very infectious and quickly spreadable. So forbidding the spreading of the disease caused by SARS-CoV-2 is now the biggest problem in most countries around the globe. That is why screening potentially infected persons is recommended at the early stages of infection.
How to diagnose the SARS-CoV-2 infection?
Following the WHO recommendations, PCR tests are used to identify virus genetic material. They are most sensitive between the 7th and 14th day after contact with SARS-CoV-2 when you may see the first symptoms of the infection.
After about a week after discovering the first clinical symptoms, the sensitivity of molecular diagnosis (PCR) of the SARS-CoV-2 infections decreases with time because of fewer viral particles in the respiratory epithelium. Then a patient can get a false negative test result despite the actual disease.
At later stages, more critical are serological tests that can find specific SARS-CoV-2 antibodies. Those perfectly complement the PCR technique by prolonging the period required to make a test more precise.
What is the IgA antibody SARS-CoV-2 test?
After meeting the CoV-2 coronavirus, the immune system starts fighting a pathogen. The organism activates various protection mechanisms and produces specific antibodies that can be found with the EIA. The studies showed that the precisest results could be achieved by measuring two classes of antibodies: IgA and IgG.
SARS-CoV-2 IgA is a specialized enzyme immunoassay kit designed by a group of experts based on the latest scientific reports. It serves for qualitative and semi-quantitative identification of specific IgA antibodies to SARS-CoV-2 in blood, which confirms that a patient contacted with the virus. The test is based on an “indirect” solid-phase type of enzyme immunoassay.
When and under which circumstances do you need an antibody test?
The identification of specific IgA antibodies to SARS-CoV-2 becomes possible after 10 days after arising of the first clinical symptoms of the infection. Discovering the antibodies is considered a confirmation of contact with the coronavirus, which is essential to:
- determine infected people without or with light symptoms which can be a source of infection for other persons (so-called “silent” carriers);
- screen people possibly contacted with those who are infected with SARS-CoV-2 but do not correspond to requirements to make a PCR test;
- examine people, especially those with confirmed direct contact with the coronavirus infection SARS-CoV-2 (for instance, hospital personnel);
- make decisions about quarantine measures, their prolongation or end;
- work with patients with complications after a recent influenza-like infection, which didn’t pass a coronavirus test;
- perform epidemiological studies to define the spreading of disease among the population. It is not recommended to make an IgA antibody test at the early stages of the disease. This is because the serological diagnosis provides for a so-called “gap” when specific antibodies cannot be found in the patient’s blood. Their quantity is pretty low at the initial stage of infection, so that that test results can be negative.